Shares of Novo Nordisk plunged more than 16%, erasing the remaining gains driven by its blockbuster weight-loss drug Wegovy. The sharp decline followed disappointing trial results for its next-generation obesity treatment CagriSema, which underperformed a rival therapy from Eli Lilly. The drop pushed Novo’s valuation sharply lower, extending a massive fall from its 2024